Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of paclitaxel-induced sensory peripheral neuropathy
      QxMD      Google Scholar   
Citation:
Clin. Cancer Res. vol 19 (2) 491-499
Year:
2013
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
Yes
DataSharing:
No
Book Volume:
2
Parents:
None
Children:
None
Program:
TRP
Primary Committee:
PPP
Sec. Committees:
   
Pharmas:
 
Grants:
F32 CA165823, P50CA125183, U01 GM061393, P50 CA125183, U10 CA031946, U01GM61393, U10 CA033601, T32 CA009594, P30 CA008748, F32CA165823, U01 GM061390, U19 GM061390, U01GM61390, T32 CA009566, T32CA009594, CA31946, T32CA009566  
Corr. Author:
 
Authors:
                                         
Primary Study
CALGB-40101
Secondary Studies:
Phases:
3
Keywords:
pharmacogenomics, clinical trial, cell lines, paclitaxel, genome-wide association